Highlights Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Market Closed - Nasdaq Other stock markets 21:30:00 20/05/2024 BST			5-day change	1st Jan Change
3.034 ^USD	-8.07%		-13.47%	-38.71%

05-06	Genenta Science S.p.A. Announces New Board Appointments	CI
04-08	Genenta Science S.P.A. Announces Resignation of Board Members	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genenta Science S.p.A. Announces New Board Appointments	05-06	CI
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	02-08	CI
Sandoz to Acquire Cimerli Business from Coherus for $170 Million	01-22	DJ
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20/10/23	CI
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28/07/23	CI
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	21/04/23	CI
Genenta Science S.p.A. Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications	03/04/23	CI
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme	02/03/23	CI
Genenta Science Signs Development, Manufacturing Deal With AGC Biologics	07/02/23	MT
Genenta Science S.P.A. and Ospedale San Raffaele S.R.L. Enters into License Agreement	22/12/22	CI
Genenta Science S p A : Unaudited Consolidated Financial Statements as of June 30, 2022, and for the six months ended June 30, 2022, and June 30, 2021 - Form 6-K	25/10/22	PU
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	25/10/22	CI
Genenta Provides First Half 2022 Business Update and Financial Results	24/10/22	AQ
Genenta Science S.P.A. Announces Ongoing Trial of Temferon™	04/05/22	CI
Genenta Science Announces Preliminary Findings from its Phase 1/2A of Temferon™ in the Treatment of Patients with Glioblastoma	02/05/22	CI
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	02/05/22	CI
Genenta Announces Nomination of Mark A. Sirgo as Chair	27/04/22	AQ
Genenta Closes Its Upsized Initial Public Offering of American Depository Shares	17/12/21	AQ
Genenta Science S.p.A. has completed an IPO in the amount of $35.881311 million.	15/12/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Highlights

Filters